Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended ...
Immunovant, Inc. (IMVT)
Company Research
Source: GlobeNewswire
Immunovant plans to initiate two placebo-controlled Phase 3 clinical trials of batoclimab in thyroid eye disease (TED) in the second half of calendar year 2022 with top-line data expected for both in the first half of calendar year 2025Immunovant estimates annual addressable U.S. TED population for a new mechanism of action to be 8,000-18,000 patientsImmunovant on track to initiate pivotal Phase 3 clinical trial of batoclimab in myasthenia gravis (MG), by the end of June 2022Cash balance of $494 million as of March 31, 2022 expected to provide cash runway into calendar year 2025 NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it has achieved alignment with the United States Food and Drug Administration (FDA) Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 clinical trials to evaluate batoc
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $48.00 price target on the stock.MarketBeat
- Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday [Yahoo! Finance]Yahoo! Finance
- HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
IMVT
Earnings
- 2/12/24 - Beat
IMVT
Sec Filings
- 2/23/24 - Form 4
- 2/23/24 - Form 4
- 2/23/24 - Form 4
- IMVT's page on the SEC website